NSE · Healthcare · Drug Manufacturers - General
EPS came in at 5.08 against a street estimate of 4.40 — a beat of 15.5%.
with an average price target of ₹1,897.50.
| Document | Date |
|---|---|
| Q1 FY27 earnings call RUBICON RESEARCH LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from operations: INR 534 crores (Q1 FY27) – 51% YoY growth • EBITDA: | 2026-08-19 |
| Annual report FY2026 RUBICON RESEARCH LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from operations (FY 2025-26): ₹13,060.82 million (up 21 | 2026-08-14 |
| Investor presentation · Q1 FY27 RUBICON RESEARCH LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue from Operations: ₹5,343 Million (up 51.6% YoY from ₹3,525 Million in | 2026-08-14 |
| Quarterly results · Q1 FY27 RUBICON RESEARCH LIMITED – Q1 FY2026-27 FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone Revenue from Operations (Q1 FY27): ₹4,277.30 million vs ₹2,7 | 2026-08-14 |
| Investor presentation | 2026-08-14 |
| Annual report FY2026 RUBICON RESEARCH LIMITED – FINANCIAL SUMMARY FY 2025-26 HEADLINE NUMBERS • Revenue from operations: ₹13,060.82 million (FY2025: ₹10,738.43 million) | 2026-08-03 |
| Q4 FY26 earnings call RUBICON RESEARCH LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 5,140 million, +44% year-on-year; +8% sequentially • Q4 | 2026-06-02 |
| Investor presentation · Q4 FY26 RUBICON RESEARCH LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q4 FY2026 Revenue from Operations: ₹5,139 million (Q4 FY2025: ₹3,581 million) – growt | 2026-05-29 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1.50 / share ex-date Aug 7, 2026 | 2026-08-07 |
| Announcement | Date |
|---|---|
| Acquisition of manufacturing facility in USA announced Rubicon Research Limited has acquired its first US manufacturing facility in East Brunswick, New Jersey from InvaTech Pharma Solutions for USD 2.9 million through its wholly-owned subsidiary | 2026-07-22 |
| Merger of subsidiary Kia Health Tech Private Limited with parent company Rubicon Research Limited announced two key corporate actions: First, the Board scheduled its 27th Annual General Meeting for August 26, 2026 (virtual format) and set the record date as Augus | 2026-07-20 |
| Acquisition of another business completed Rubicon Research Limited has announced the acquisition of an 85% stake in Arinna Lifesciences Limited, a branded pharmaceutical company, for approximately INR 175.92 crores (enterprise value | 2026-04-15 |
| In-principle approval granted for merger transaction Rubicon Research Limited announced four board-level decisions on February 3, 2026: 1. **New Director**: Appointed Dr. Pradnya Saravade as an Additional Independent Woman Director for three | 2026-02-03 |
| Acquisition of Rubicon Research Limited Rubicon Research Limited has signed a definitive agreement to acquire up to 10.5% stake in Neuronasal Inc., a US-based clinical-stage pharmaceutical company, for up to USD 2.5 million. The i | 2025-10-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rubicon Research Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.